- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07789678
Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021 in Brazil (BRIGHT)
A Single-arm Observational Study to Characterize the Epidemiological Profile of Patients With IDH-mutant Diffuse Gliomas Diagnosed From 2021 in Brazil - BRIGHT Study (LACOG 0425)
This is a real-world, retrospective, non-interventional, single-arm, multi-center Brazilian study that will include patients diagnosed with IDH-mutant diffuse glioma in Brazil from 2021. Eligible patients will be included in this study to have their medical charts data collected by site personnel. Included patients won´t be requested to attend protocol-specific visits and treatment decisions and disease management will be at the investigator's discretion
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This study is designed to describe the epidemiological, anti-cancer treatment and clinical outcomes of patients with IDH-mutant diffuse glioma in Brazil. Patients ≥ 12 years old diagnosed with IDH-mutant diffuse gliomas from 2021 will be included. In the baseline medical chart evaluation, data on epidemiology, pathological, treatment patterns, toxicities, and clinical outcomes will be collected. LACOG (Sponsor) will be responsible for managing data from this study, including quality verification. Manually entered data will be captured via EDC using eCRFs. The EDC system used in this study will be REDCap (Research Electronic Data Capture) - that meets the established standards approved for the safety of health information and is validated. REDCap is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for continuous data downloads for common statistical packages; and 4) procedures for data integration and interoperability with external sources. The system also meets ICH guidelines on electronic handling of study data and will be available for audit upon request. Patient confidentiality will be strictly maintained.
An informed consent form will be offered to all living patients. The consent will be unnecessary in patients that could not be reached or that have passed away (died) as per regulation Res. CNS 466/12 item IV.8. Consent will be obtained from legal guardians for patients between the ages of 12 and 17 years old as per Brazilian regulation.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Laura Voelcker
- Telefoonnummer: +55 (51) 3384.5334
- E-mail: laura.voelcker@lacog.group
Studie Contact Back-up
- Naam: Project Manager
- Telefoonnummer: +55 (51) 3384.5334
- E-mail: lacog0425@lacog.group
Studie Locaties
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazilië, 40050-050
- Nog niet aan het werven
- IESG Instituto de Ensino da Saúde e Gestão
-
Hoofdonderzoeker:
- Teresa Fonseca
-
Salvador, Estado de Bahia, Brazilië, 40050-410
- Nog niet aan het werven
- Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel (Oncoclínicas)
-
Hoofdonderzoeker:
- Daniela Oliveira
-
Salvador, Estado de Bahia, Brazilië, 41950-640
- Nog niet aan het werven
- ÉTICA Clínica AMO - Assistência Multidisciplinar em Oncologia
-
Hoofdonderzoeker:
- Aknar Calabrich
-
-
Federal District
-
Brasília, Federal District, Brazilië, 70390-140
- Nog niet aan het werven
- OncoStar Rede D'or DF
-
Hoofdonderzoeker:
- Daniel Marques
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazilië, 30360-680
- Nog niet aan het werven
- Oncocentro de Minas Gerais (Oncoclínicas)
-
Hoofdonderzoeker:
- Flávio Brandão
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazilië, 90470-340
- Werving
- Futtura Oncologia - Hub de Pesquisa Clínica
-
Hoofdonderzoeker:
- Luisa Fasolo
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brazilië, 20230-130
- Nog niet aan het werven
- INCA - Instituto Nacional de Câncer
-
Contact:
- Telefoonnummer: +5521991169827
-
Hoofdonderzoeker:
- Carolina Pessôa
-
Rio de Janeiro, Rio de Janeiro, Brazilië, 22793-080
- Nog niet aan het werven
- Instituto COI - Clínicas Oncológicas Integradas (Instituto Américas RJ)
-
Hoofdonderzoeker:
- Victor Teixeira
-
-
São Paulo
-
São Paulo, São Paulo, Brazilië, 01308-050
- Nog niet aan het werven
- Hospital Sírio-Libanês SP
-
Hoofdonderzoeker:
- Marcos Maldaun
-
São Paulo, São Paulo, Brazilië, 01323-030
- Nog niet aan het werven
- BP - A Beneficência Portuguesa de São Paulo
-
Hoofdonderzoeker:
- Camilla Yamada
-
São Paulo, São Paulo, Brazilië, 04039-001
- Nog niet aan het werven
- GRAACC - Grupo de Apoio ao Adolescente e à Criança com Câncer
-
Hoofdonderzoeker:
- Andrea Cappellano
-
São Paulo, São Paulo, Brazilië, 05653-000
- Nog niet aan het werven
- HIAE - Hospital Israelita Albert Einstein
-
Hoofdonderzoeker:
- Suzana Malheiros
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Male or female patients (aged 12 years or older), able to provide informed consent, diagnosed with IDH-mutant diffuse glioma in Brazil from 2021.
Beschrijving
Inclusion Criteria:
- Male or female patients (aged 12 years or older);
- Histologically confirmed diagnosis of diffuse glioma from 2021;
- Confirmed IDH mutation identified by IHC or PCR/NGS;
- Willing and able to provide written informed consent, applicable to living patients. In case of patients <18 years of age, their legal guardians should provide an written informed consent
Exclusion Criteria:
Since the study is observational, there are no extensive Exclusion Criteria, but the following criteria excludes patients from the study to ensure data collected by be analyzed from a broader context and compared to other studies of this kind:
- Patients without medical record available (lost, empty or irretrievable clinical information).
- Living patients and/or legal guardians of patients <18 years of age who did not accept or withdrew their consent from the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: RETROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
IDH-mutant diffuse glioma cohort
Male or female patients aged 12 years or older histologically confirmed diagnosis of diffuse glioma from 2021 and confirmed IDH mutation identified by IHC or PCR/NGS. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Epidemiological profile of patients with IDH-mutant diffuse gliomas
Tijdsspanne: Baseline
|
Characterization of demographic and socioeconomic characteristics, including age, weight, height, race, educational level, income, marital status, living status, and risk factors |
Baseline
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS)
Tijdsspanne: From date of diagnosis up to at least 30 months.
|
Date of initial diagnosis/treatment to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed via CNS imaging per investigator assessment. |
From date of diagnosis up to at least 30 months.
|
|
Overall Survival (OS)
Tijdsspanne: From date of diagnosis up to at least 30 months.
|
Percentage of participants alive and time from diagnosis to death from any cause. |
From date of diagnosis up to at least 30 months.
|
|
Objective Response Rate (ORR)
Tijdsspanne: Up to 30 months.
|
Evaluation of objective tumor response to therapies assessed via central nervous system (CNS) imaging by investigator assessment. |
Up to 30 months.
|
|
Treatment Patterns and Sequencing
Tijdsspanne: Up to 30 months.
|
Characterization of systemic therapies, radiation therapy details (dose, fractions), surgical procedures, and treatment sequencing. |
Up to 30 months.
|
|
Dose Reduction and Discontinuation Rates
Tijdsspanne: up to 30 months
|
Percentage of participants requiring dose reduction or treatment discontinuation and reasons for modification/discontinuation. |
up to 30 months
|
|
Time to Next Intervention (TTNI)
Tijdsspanne: Up to 30 months.
|
Time from the date of first systemic therapy initiation to the date of initiation of subsequent anticancer therapy. |
Up to 30 months.
|
|
Interval Between Last Surgery and First Systemic Therapy or Radiotherapy
Tijdsspanne: Baseline/up to 30 months
|
Median interval in days/months between the date of the last glioma surgery and the initiation of the first systemic therapy or radiotherapy. |
Baseline/up to 30 months
|
|
Time From Initial Diagnosis to First Systemic or Radiotherapy Initiation
Tijdsspanne: Baseline/up to 30 months
|
Time in days/months from the date of initial pathological diagnosis to the start of first systemic therapy or radiotherapy. |
Baseline/up to 30 months
|
|
Prevalence of Seizures at First Systemic Therapy
Tijdsspanne: up to 30 months
|
Percentage of patients experiencing seizures for any reason at or during the initiation of the first systemic therapy. |
up to 30 months
|
|
Karnofsky Performance Status (KPS) Score
Tijdsspanne: Baseline/up to 30 months
|
Functional status evaluated using the Karnofsky Performance Status scale (range 0-100%). |
Baseline/up to 30 months
|
|
Karnofsky Performance Status (KPS) Deterioration
Tijdsspanne: up to 30 months
|
Assessment of KPS score decline/deterioration over time during the first systemic therapy. |
up to 30 months
|
|
Frequency and Results of Molecular Testing
Tijdsspanne: Baseline
|
Description of the proportion and specific results of molecular testing (e.g., IDH mutation testing by IHC or PCR/NGS, 1p/19q codeletion, CDKN2A/B) performed in routine clinical practice in Brazil. |
Baseline
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Carolina Pêssoa, Instituto Nacional do Câncer
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- LACOG 0425
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .